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1In the 1960s, the basic concept of blood pressure (BP) response to salt-intake was proposed.1 In the direct measure-
ment of the hemodynamics of partially-nephrectomized dogs, 
it was demonstrated that the daily infusion of isotonic saline 
led to an increase in the cardiac output and BP within a few 
days, which was associated with a slight decrease in the total 
peripheral vascular resistance. The results of numerous animal 
and human studies2,3 confirmed Guyton proposal that the renal 
dysfunction primarily induces hypertension, and this has been 
accepted as the basic mechanism of salt-sensitive hypertension.
Almost all genetic variants identified in patients with 
Mendelian hypertensive disorders were found at the genetic 
loci associated with renal sodium-transporting system, such 
as WNK1/4 gene in Gordon syndrome,4 SCNN1B/G in Liddle 
syndrome,5,6 and HSD11B2 in the apparent mineralocorticoid 
excess (AME) syndrome.7 These reports further supported 
Guyton proposal, even though Mendelian hypertensive disor-
ders account for <1% of all human hypertension cases.
However, some scientists have recently expressed their 
criticism of Guyton proposal, questioning the primary role 
of renal dysfunction in the development of hypertension, 
suggesting that the observed genetic variations in patients 
with Mendelian hypertensive disorders may play a role in 
extrarenal organs as well, such as vasculature and brain.8 
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These genes were, indeed, shown to be expressed in both 
kidneys and other tissues.9–11 Therefore, it is necessary to 
examine whether an impaired regulation of the renal sodium 
transport represents a primary cause of salt-sensitive 
hypertension.
To elucidate this, we focused on the loss-of-function muta-
tions of HSD11B2 gene, found in patients with AME syn-
drome. 11β-Hydroxysteroid dehydrogenase (11β-HSD2 and 
HSD11B2) converts glucocorticoids to their inactive form 
and maintains the sensitivity of mineralocorticoid receptor 
(MR) to mineralocorticoids because glucocorticoids can bind 
to MR, and they are found in plasma at the concentrations 
100× to 1000× higher than mineralocorticoids.12,13 Therefore, 
the development of hypertension in patients with AME 
syndrome may potentially be ascribed to the aberrant acti-
vation of MR and epithelial sodium channel (ENaC) in the 
kidney. However, previous studies using Hsd11b2 knockout 
mice reported that the natriuretic response to ENaC blockers 
did not differ between the knockout mice and the wild-type 
(WT) controls, which casts some doubt on the renal origin 
of salt-sensitive hypertension in this AME animal model.14 
Furthermore, brain-specific Hsd11b2 knockout mice were 
shown to have a normal BP when fed with normal salt diet but 
extremely high-salt diet led to hypertension with impaired 
baroreflex,15 which was associated with the hypertension 
ascribed to the increased production of catecholamines in the 
global knockout mice on normal salt diet.16 These results sup-
port the “neuro-vascular” hypothesis, but plasma levels of cat-
echolamines were normal in a patient with AME syndrome.17 
It is, therefore, still unknown how HSD11B2 deficiency leads 
to hypertension without high-salt intake, as observed in the 
global Hsd11b2 knockout mice and in patients with AME 
syndrome.
To examine whether renal dysfunction plays a decisive 
role in the development of hypertension in patients with AME 
syndrome, we generated kidney-specific Hsd11b2 knock-
out (Hsd11b2Ksp−/−; knockout) mice by using kidney-specific 
cadherin (Ksp) promoter-controlled Cre/LoxP system.18 We 
demonstrate that Hsd11b2Ksp−/− mice developed hypertension 
even with normal salt intake through the activation of renal 
MR–ENaC, which lead to hypokalemia and Na+-Cl– cotrans-
porter (NCC) phosphorylation. Our data elucidate the under-
lying mechanisms of hypertension and the importance of renal 
dysfunction in developing AME syndrome.
Methods
Precise methods are available only in the online-only Data 
Supplement.
Animals
Animal care and treatment complied with the standards described 
in the Guidelines for the Care and Use of Laboratory Animals of 
the University of Tokyo, Japan. We used 8- to 20-week-old male 
C57BL/6-background Hsd11b2Ksp−/− mice and the age-matched Cre-
negative male mice as WT control. All animals had free access to 
drinking water and diet and were grown under the temperature-con-
trolled conditions, with 12 hours/12 hours of light (8:00 am to 8:00 
pm)/dark (8:00 pm to 8:00 am). Normal-salt diet contained ≈0.35% 
Na+, whereas low-salt diet contained 0.01% Na+. High-potassium 
diet contained 8% potassium chloride (KCl). Amiloride (25 mg/L) 
and hydrochlorothiazide (300 mg/L) were administered through the 
drinking water. Slow-release pellets containing spironolactone (min-
eralocorticoid receptor antagonist, MRA; Innovative Research of 
America, Sarasota, FL) were produced to be capable for releasing the 
drug continuously for 21 days at the dose of 50 mg/kg body weight/d. 
The pellet was subcutaneously implanted into the neck. Chronic 
treatments of amiloride, 8%KCl diet, hydrochlorothiazide, and MRA 
were continued for 10 days. Before the surgery or euthanization, the 
animals were inhalationally anesthetized with 1.5% isoflurane.
BP Measurement
Arterial BP in conscious mice was directly monitored by catheteriza-
tion of left carotid artery with radiotelemetry.
Antibodies
Primary antibodies used in this study were as follows: anti-ENaCα19 
(1/5000 for Western blotting [WB]), anti-NCC (1/5000 for WB, 
AB3553; Millipore), anti-pNCC T5319 (1/5000 for WB), and anti-
NKCC2 (1/5000 for WB, AB3562P; Abcam).
Statistical Analysis
The data are presented as mean± SEM. Comparisons between 2 
groups were performed by using the Welch t test. Multiple compari-
sons were performed by using ANOVA with post hoc Bonferroni–
Holm test. P<0.05 was considered statistically significant.
Results
Kidney-Specific Gene Deletion of Hsd11b2
Initially, we confirmed kidney-specific deletion of Hsd11b2 
gene in Hsd11b2Ksp−/− mice. Western blotting and real-time 
polymerase chain reaction analyses revealed that HSD11B2 
expression is significantly decreased in the knockout mouse 
kidneys compared with that in the WT mouse kidneys, 
although colon expression did not differ between these mice 
(Figure S1A and S1B). Renal expression of HSD11B1 did 
not change (Figure S2). Double AQP2 and HSD11B2 stain-
ing showed that HSD11B2 colocalized in renal principal cells 
of the WT mouse kidneys, whereas the knockout mouse kid-
neys completely lacked the expression of HSD11B2 (Figure 
S1C). We also checked whether gene expressions were 
altered in aorta and brain stem of the knockout mice, which 
might regulate BP through modulating vascular resistance 
or sympathetic nervous system (SNS) activity. As expected, 
Hsd11b2 gene expression was significantly decreased only in 
the knockout kidney and Hsd11b1 gene expression was not 
altered between the genotypes in all of these tissues (Figure 
S3). The ratio of 11-dehydrocorticosterone to corticosterone 
in urine samples was significantly decreased in the knockout 
mice (Figure S4A).
Hypertension Is Salt-Dependent in Kidney-Specific 
Knockout Mice
We evaluated whether kidney-specific deletion of Hsd11b2 
gene affects BP and measured significantly higher systolic, 
diastolic, and mean arterial BP (MBP) values in the knockout 
mice than those determined in the WT mice by radiotelemetry 
(Figure 1A, 1B, and 1D), while both groups of mice were fed 
with normal salt diet and their food intake was at almost the 
same level (Figure S4B and S4C). Heart rate was significantly 
lower in the knockout mice than in the WT mice (Figure 
1C). Although the elevation in systolic BP of the knockout 
mice was also confirmed by tail-cuff method (Figure S5A), 
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Ksp-Cre transgene did not affect systolic BP in mice harbor-
ing WT Hsd11b2 gene (Figure S5B). As expected, reducing 
dietary salt intake led to the normalization of the MBP in the 
knockout mice, reducing it to the levels determined in the WT 
mice (Figure 1E).
Hypokalemia and Suppression of the RAAS
Furthermore, both plasma aldosterone concentration and 
renin activity were significantly lower in the knockout mice 
than in the WT mice (Figure 2A and 2B), whereas corticos-
terone levels were not altered (Figure 2C). Hypokalemia 
represents another major symptom of AME syndrome. Here, 
we showed that plasma potassium levels were significantly 
reduced in the knockout mice compared with those in the 
WT mice (Figure 2D). Previously, hypokalemia observed in 
patients with AME syndrome has been described as a result 
of ENaC activation in the kidney, leading to the lowering of 
the urinary excretion of sodium and the increased excretion 
of potassium.
Acute Diuretic Response by Amiloride
Although it was previously reported that the increase in 
urinary sodium excretion induced by the ENaC blocker 
did not differ between global Hsd11b2 knockout mice and 
their WT controls,14 in our study, the acute natriuretic effect 
of ENaC blocker amiloride was shown to be significantly 
increased in the knockout mice, compared with that in the 
WT mice. Fractional excretion rate of sodium was signifi-
cantly increased after the acute administration of amiloride 
in the knockout mice compared with that in the WT mice 
(Figure 3A). In addition, a decreased sodium/potassium 
excretion ratio was determined in the knockout mice treated 
Figure 1. Salt-dependent blood pressure elevation in the kidney-
specific Hsd11b2 knockout (KO) mice. Systolic (SBP, A) and 
diastolic (DBP, B) arterial blood pressures and heart rate (HR, C) 
were measured for 3 d and averaged in Hsd11b2KSP−/− mice (n=7; 
filled triangles and solid line, KO) and flox-controlled littermates 
(n=7; open circles and dotted line, WT). Mean arterial blood 
pressure (MBP, D) was calculated from the obtained SBP and 
DBP values. ZT, zeitgeber time: ZT 0 to 12 is a light phase (white) 
and ZT 12 to 24 is a dark phase (gray) in a day. E, Averaged MBP 
values of Hsd11b2KSP−/− mice (n=4; filled triangles and solid line, 
KO) and flox-controlled littermates (n=4; open circles and dotted 
line, WT) in every 3 h are presented. MBP values of each group 
under normal salt diet (left dotted box) and low salt diet (right 
dotted box) were shown as mean±SEM and statistically analyzed 
by using 2-way ANOVA with post hoc Bonferroni–Holm test to 
assess the effects of the variables; genotype and time (A through 
D) or diet (E). *P<0.05, compared with the control in the same 
period.
Figure 2. Apparent mineralocorticoid excess-like phenotypes 
observed in the kidney-specific Hsd11b2 knockout (KO) 
mice. Blood samples were collected at the euthanization of 
Hsd11b2KSP−/− mice and flox-controlled littermates at around 
8:00 pm. Plasma aldosterone levels (A), renin activity (B), and 
corticosterone levels (C) were determined (WT, wild-type [n=5]; 
KO [n=6]). Plasma potassium concentrations (D) were determined 
immediately after the euthanization using i-STAT (n=5 for each 
genotype). All data are shown as mean±SEM and statistically 
analyzed by using Welch t test. *P<0.05, compared with the 
control. N.S. indicates not significant.
 by guest on N
ovem
ber 20, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
4  Hypertension  July 2017
with vehicle, in comparison with that in the vehicle-treated 
WT mice (Figure 3B) and, higher sodium/potassium excre-
tion ratio in the amiloride-treated knockout mice was mea-
sured, compared with that in the amiloride-treated WT mice 
(Figure 3C).
Renal Membrane Expressions of Sodium 
Transporters
Furthermore, we evaluated the effect of kidney-specific 
HSD11B2 deficiency on the expression levels of sodium 
transporter proteins on membrane fractions (Figure S6) 
in the distal nephron, to determine the precise mechanism 
of aberrant sodium reabsorption in the knockout kidney. 
Western blot analyses of renal membrane fractions revealed 
an increase in the expressions of ENaCα and its cleaved 
form (Figure 4A and 4B), which were reported to be positive 
markers of ENaC activity.19 NCC and T53-phosphorylated 
NCC19 levels were shown to be increased in the membrane 
fractions of the knockout mouse kidneys, while those of the 
sodium–potassium–chloride transporter (NKCC2) were not 
altered.
Hypertension and Hypokalemia-Induced Activity of 
NCC
On the basis of the recent reports demonstrating that low 
plasma potassium levels lead to the phosphorylation of NCC,20 
we hypothesized that hypokalemia led to the activation of 
NCC in the knockout kidneys, and that NCC upregulation 
may be reversed by regulating the potassium levels. To test this 
hypothesis, we induced the elevation of plasma potassium lev-
els in the knockout mice by chronically administering ENaC 
inhibitor, amiloride, or by applying 8% KCl diet (Figure 5A). 
As expected, the levels of T53-phosphorylated NCC in the 
knockout mouse kidneys decreased to the levels determined in 
the WT kidneys, whereas the levels of cleaved ENaCα were 
considerably increased after these treatments (Figure 5B and 
5C; Figure S7), which was most likely affected by the plasma 
potassium level-induced aldosterone upregulation.
The effects of hypokalemia-induced NCC activation on 
BP were analyzed by increasing plasma potassium levels in 
the knockout mice. We showed that the chronic administra-
tion of amiloride (Figure 5D; Figure S8A) and 8% KCl diet 
(Figure 5E; Figure S8B) led to a decrease in the MBP values 
in the knockout mice to the levels determined in the WT mice. 
In addition, the MBP values in the knockout mice were sig-
nificantly decreased, to the level of the WT mice, after the 
chronic administration of the NCC inhibitor, hydrochlorothia-
zide (Figure 5F; Figure S8C).
MR Dependency of the Hypertension
Finally, we aimed to examine whether MR is responsible for 
developing hypertension in the knockout mice. We subcu-
taneously administered slow-release pellets containing MR 
antagonist spironolactone to the knockout mice and measured 
their BPs. As a control, we administered MRA to the WT 
mice and measured their BP levels as well. We observed that 
MBP values significantly decreased after the administration 
of spironolactone in the knockout mice (Figure 6A), although 
MRA did not affect MBP values in the WT mice (Figure 6B). 
By chronic MRA treatment for 7 days, the expression level 
of cleaved ENaCα was significantly decreased in membrane 
fractions of the knockout kidney to the level of the WT kid-
ney and NCC phosphorylation was partially but significantly 
decreased from its baseline (Figure 6C). Interestingly, renal 
NKCC2 was also decreased by chronic MRA treatment in 
membrane fractions of the knockout kidney (Figure 6C), in 
contrast to the no effects of amiloride or 8% KCl diet on the 
levels of renal NKCC2 (Figure 5B and 5C).
Discussion
Our analyses suggested that the complete kidney-specific 
deletion of Hsd11b2 gene was achieved in the kidneys of 
Figure 3. Acute amiloride test results of kidney-specific Hsd11b2 
knockout (KO) mice. Change of urinary fractional excretion ratio 
of sodium (ΔFENa; A) and urinary Na/K ratio in mice treated with 
vehicle and in those treated with amiloride (B) were analyzed 
using urine and blood samples (n=6 for each genotype). Data are 
shown as mean±SEM and statistically analyzed by using Welch t 
test. *P<0.05, compared with the control. WT indicates wild-type.
Figure 4. Upregulation of cleaved epithelial sodium channel-α 
(ENaCα) and phosphorylated NCC in the kidney of kidney-
specific Hsd11b2 knockout (KO) mice. A, The same amount of 
membrane fractions of kidney lysates were analyzed by Western 
blotting (WB). B, The expression levels, which were calculated 
from the intensities of WB band corrected by those of coomassie 
brilliant blue (CBB) staining (n=5 for each genotype), are shown 
as mean±SEM and statistically analyzed by Welch t test between 
the genotypes. *P<0.05, compared with the control. CL indicates 
cleaved form; FL, full length; N.S., not significant; and WT, wild-
type.
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Hsd11b2Ksp−/− mice. The results showing that the aldosterone 
levels and renin activity in plasma were lower, whereas the 
concentration of corticosterone was not altered in the knock-
out mice, in comparison with those in the WT mice, suggested 
that MBP elevation in the knockout mice can be attributed 
to sodium retention induced by kidney-specific induction of 
corticosterone levels, which leads to the suppression of cir-
culating renin–angiotensin–aldosterone system. In addition, 
the obtained results were consistent with our hypothesis that 
HSD11B2 deficiency in the kidney is sufficient for the devel-
opment of hypertension and other AME-like phenotype.
Recently, the mechanism of salt-sensitive hypertension 
has been vigorously discussed, which was initiated by the 
criticism of Guyton proposal. The critics highlighted the 
lack of normotensive subjects as controls for salt-sensitive 
hypertensive subjects, which showed a greater salt load–
induced elevation of BP, primarily caused by fluid retention 
and followed by an increase in the total peripheral vascular 
resistance, in comparison with that in the nonsalt-sensitive 
hypertensive subjects.8 Morris et al8 reported the results 
of a study including human normotensive subjects. In the 
study, BP was elevated immediately after the salt loading 
in salt-sensitive subjects and the total peripheral vascular 
resistance decreased less, before an increase in the cumula-
tive sodium balance was greater, in comparison with those 
in the salt-resistant subjects. The authors thus proposed that 
Figure 5. Effects of renal NCC activation on blood pressure levels 
in the kidney-specific Hsd11b2 knockout (KO) mice. A, Plasma 
potassium concentrations of Hsd11b2Ksp−/− mice after treatment, 
amiloride (KO+Amil) or KCl diet (KO+KCl) and those of the control 
groups (wild-type [WT], KO) are shown (n=5 for each group). B, 
Results of Western blotting for transporter proteins in membrane 
fractions of kidney lysates and CBB staining; each WB band was 
quantified and corrected by the CBB intensity in the lane (C). BP 
recordings at baseline were obtained for 72 h, before the initiation 
of any treatment, and lasted for 10 d. The 3-h MBP in amiloride 
(D), 8% KCl diet (E), and hydrochlorothiazide (HCTZ, F) treated 
animals (n=3 in each group) are presented. Data are shown as 
mean±SEM and statistically analyzed by 1-way ANOVA and 
post hoc Bonferroni-Holm test (A, C) or 2-way ANOVA and post 
hoc Bonferroni–Holm test to assess the effects of the variables; 
genotype, and treatment. *P<0.05 compared with the WT control; 
†P<0.05, compared with KO; ‡P<0.05, compared with WT in the 
same period. N.S. indicates not significant.
Figure 6. Effects of mineralocorticoid receptor (MR) antagonist 
spironolactone on the blood pressure levels of kidney-specific 
Hsd11b2 knockout (KO) mice. After BP recording at baseline 
in Hsd11b2Ksp−/− mice (KO, A) and the wild-type (WT) controls 
(B) during days 1 to 3, a pellet containing spironolactone 
(MRA) was implanted to each group of mice (n=3) and blood 
pressure (BP) recording was continued until day 10. Averaged 
3-h mean BP (MBP) are shown. Two-way ANOVA with post hoc 
Bonferroni–Holm test was performed to assess the effects of the 
valuables; genotype, and MRA treatment. *P<0.05, compared 
with the baseline values. C, Renal membrane fractions of MRA-
treated KO mice and the control groups (WT, KO) were analyzed 
by Western blotting for sodium transporter proteins; each band 
was quantified and the result was corrected by the intensity of 
CBB staining. These data were statistically analyzed by 1-way 
ANOVA with post hoc Bonferroni–Holm test. All data were shown 
as mean±SEM. *P<0.05, compared with WT; †P<0.05, compared 
with KO. CL indicates cleaved form; and FL, full length.
 by guest on N
ovem
ber 20, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
6  Hypertension  July 2017
vasodilatation dysfunction precedes the initiation of salt-sen-
sitive hypertension.
In contrast, Hall et al3 pointed out the lack of evidence dem-
onstrating a decisive contribution of the abnormal nonrenal 
vascular resistance to the initiation of salt-sensitive hyperten-
sion. It was suggested that abnormal renal vascular resistance 
may have a role in the impaired renal sodium handling, and 
several studies investigating hypertension by kidney-specific 
manipulations were cited.3 However, kidney-specific gene 
manipulations were not used to confirm the importance of 
gene mutations found in Mendelian hypertensive disorders for 
the development of renal dysfunction and systemic hyperten-
sion. Therefore, the possible nonrenal effects of these gene 
mutations should be considered as well.
Our aim was to determine whether kidney-specific gene 
mutations found in patients with AME syndrome can cause 
renal dysfunction leading to salt-dependent hypertension. 
Considering the increased activity of ENaC in the knock-
out mouse kidneys in comparison with the WT kidneys and 
the normalization of their BP after the amiloride treatment, 
we suggest that ENaC activation contributes to the develop-
ment of salt-dependent hypertension in the kidney-specific 
Hsd11b2 knockout mice. Furthermore, we determined that 
the activation of MR induced by the increased levels of cor-
ticosterone in the kidneys affects BP elevation in the knock-
out mice, and the application of MR antagonist showed that 
salt-sensitive hypertension can be attributed to MR activa-
tion, in aldosterone/corticosterone-dependent and aldoste-
rone/corticosterone-independent fashion.21,22 Designed in 
a more organ-specific manner than the previous studies, 
the results obtained here indicate the significance of renal 
dysfunction in explaining the mechanism underlying the 
development of Mendelian salt-dependent hypertension, 
although we did not evaluate either the cumulative sodium 
levels balance or hemodynamics such as pressure-natriure-
sis. Relative to this issue, total-body sodium storage, a large 
amount of which is sequestered in the skin, was reported to 
have a role in BP regulation.23 Further studies are needed 
to clarify where either “sodium retention” or the total body 
sodium storage is essential for the development of sodium-
dependent hypertension of our kidney-specific Hsd11b2 
knockout mice.
Chronic amiloride administration and high-KCl diet 
allowed the elucidation of the role of hypokalemia-induced 
renal NCC activation on the development of hypertension 
during renal HSD11B2 deficiency. These results suggest that 
ENaC and NCC, but not NKCC2, are activated in the knock-
out mouse kidneys, indicating that hypokalemia-induced 
NCC activation augments BP elevation induced by renal 
ENaC activation. These data support a universal significance 
of NCC activation by potassium-deficient diet-induced 
hypokalemia, as previously reported.20 The antihyperten-
sive effect of potassium was shown to be associated with 
the DOCA salt–treated hypokalemic rats24 and here with the 
kidney-specific Hsd11b2 mice as well. Furthermore, several 
studies25–28 reported a consistent decrease in BP achieved 
by potassium supplementation in hypertensive patients and 
animals with normokalemia, particularly in patients of salt-
sensitive hypertension with low plasma renin activity. In 
contrast to the effectiveness of potassium supplementation 
in “low-renin” hypertension, Veiras et al29 recently reported 
that the BP elevation in chronic angiotensin II–infused 
rats, which were normokalemic, was not affected by KCl 
supplementation, suggesting that the anti-hypertensive 
effect of potassium supplementation is less pronounced in 
“high-renin” hypertension. Besides the natriuretic effect of 
potassium supplementation, the elevation of extracellular 
potassium levels was shown to lead to vasodilatation through 
the activation of barium-sensitive potassium channels in 
vascular smooth muscle cells.30 Given high-salt-induced 
decrease in potassium-induced vasodilatation,31 however, the 
antihypertensive effect of potassium supplementation in our 
animal model of salt-dependent hypertension can be attrib-
uted to natriuresis. These results strengthened the hypothesis 
that impaired renal function rather than vascular dysfunc-
tion contributed to the development of salt-dependent hyper-
tension induced by kidney-specific Hsd11b2 gene deletion. 
Taken together, potassium supplementation may have pro-
nounced antihypertensive effects, especially in some hyper-
tensive disorders accompanied with hypokalemia or with 
low plasma renin activity, such as AME syndrome and aldo-
sterone breakthrough.32
Although brain-specific Hsd11b2 knockout mice were 
hypertensive only when fed with extremely high-salt diet,15 
our kidney-specific Hsd11b2 knockout mice, which were 
fed with normal-salt diet, developed definite hypertension, 
which was ameliorated by the administration of low-salt 
diet and diuretics, such as amiloride and hydrochlorothia-
zide. Predisposition to vasoconstriction was suggested as 
the mechanism underlying the development of hypertension 
in global and brain-specific Hsd11b2 knockout mice by the 
experiments using α1-receptor agonist phenylephrine and 
its blocker prazosin; implying the contribution of impaired 
baroreflex and increased production of catecholamines, 
respectively.15,16 In contrast, plasma levels of catecholamines 
were normal in a patient with AME syndrome.17 The dis-
crepancy between global knockout mice and patients with 
AME syndrome led us to a plausible hypothesis that, prob-
ably because of species difference in salt susceptibility of 
SNS activity, the phenotype of patients with AME syndrome 
is different from that of global knockout mice with the 
increased SNS activity, rather similar to that of the kidney-
specific knockout mice with the intact baroreflex which was 
suggested by lower heart rate than the WT control mice in 
our study. Thus, the natriuretic and the BP-lowering effects 
of amiloride in kidney-specific knockout mice, which also 
appears in patients with AME syndrome, were supposed to 
be absent in global knockout mice with the increased SNS 
activity.
Therefore, we would like to assert that kidney-specific 
knockout mice is a better rodent model than global knock-
out mice for examining the mechanism of salt-dependent 
hypertension in patients with AME syndrome. On the basis 
of the previous finding indicating that salt loading-induced 
SNS overactivity could be corrected by potassium supple-
mentation following natriuresis33,34; moreover, there are some 
possibilities that neural mechanism is secondary to salt reten-
tion in global knockout mice.35 Further study is needed to 
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evaluate the mechanism of hypertension in terms of organ 
network in Hsd11b2 knockout animals and in patients with 
AME syndrome.
Perspectives
Using the kidney-specific Hsd11b2 knockout animal model, 
we revealed hypertension and hypokalemia, which are the 
expected phenotype of AME syndrome, in these animals. We 
demonstrated for the first time that kidney-specific HSD11B2 
deficiency is sufficient for the development of the phenotype 
and that renal dysfunction is sufficient for BP increase in a 
model of Mendelian hypertension. Furthermore, we dem-
onstrated that the activities of MR and ENaC in the kidney 
have a primary role in the development of the phenotype in 
the animal model of AME syndrome. Of note, NCC activity 
was shown to have a secondary but decisive role on devel-
oping hypertension in this animal model. The results of this 
study, therefore, suggest the importance of renal dysfunction 
in the pathology of a Mendelian hypertensive disorder, AME 
syndrome.
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What Is New?
•	Kidney-specific Hsd11b2 knockout mice exhibited apparent mineralo-
corticoid excess–like phenotype including salt-dependent hypertension 
and hypokalemia with normal salt intake.
•	Mineralocorticoid receptor (MR)–epithelial sodium channel (ENaC)–hypo-
kalemia–Na+-Cl− cotransporter (NCC) pathway plays an important role in 
developing hypertension of kidney-specific Hsd11b2 knockout mice.
What Is Relevant?
•	Renal HSD11B2 deficiency is essential for developing the phenotype of 
apparent mineralocorticoid excess syndrome.
•	Not only MR and ENaC but also hypokalemia and NCC are the therapeutic 
targets in the disease state of 11β-HSD2 deficiency.
Summary
This study suggests that 11β-HSD2 deficiency in the kidney causes 
salt-dependent hypertension through MR–ENaC–Hypokalemia–
NCC pathway, thereby supporting the clinical importance of renal 
dysfunction in the pathology of Mendelian hypertensive disorders.
Novelty and Significance
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 2 
Expanded Materials and Methods 1 
 2 
Generation of Kidney-specific Knockout Animals 3 
Hsd11b2 deletion in renal tubular epithelial cells was achieved by mating 4 
C57BL/6-background transgenic mice expressing Cre-recombinase (Cre) under the 5 
control of Ksp-cadherin promoter (purchased from The Jackson Laboratory, USA), 6 
with the C57BL/6-background mice harboring Hsd11b2-floxed alleles, 1 which 7 
resulted in C57BL/6-background Hsd11b2Ksp-/- mice. During the process of generating 8 
Hsd11b2Ksp-/- mice, we also produced Ksp-Cre positive or negative mice with 9 
wild-type (non-floxed) Hsd11b2 gene, which were C57BL/6 background as well as the 10 
founders. All animals were age-matched in each experiment. 11 
 12 
Blood Analyses 13 
Animal blood samples were obtained from inferior vena cava (IVC) at the sacrifice 14 
using heparin-coated syringes and immediately analyzed electrolyte plasma 15 
concentrations by using i-STAT System 6+ Cartridge (Abbott, USA). Blood samples 16 
were centrifuged at 2300 ×g for 10 min, and the supernatants (plasma samples) were 17 
collected and stored at -80°C. Plasma aldosterone levels and renin activity were 18 
measured by radioimmunoassay, while plasma corticosterone concentrations were 19 
measured by using ELISA. 20 
 21 
Urine Analyses 22 
Before placing a mouse in a metabolic cage, the urinary bladder was emptied by 23 
abdominal massage. Urine was collected during 24 h (starting at 12 PM) from mice 24 
placed in metabolic cages. Urinary corticosterone and 11-dehydrocorticosterone 25 
contents were determined using Liquid chromatography-mass spectrometry (LC-MS).  26 
 27 
Blood Pressure Measurement Using Telemetry System 28 
Arterial BP in conscious mice was directly monitored by catheterization of left carotid 29 
artery with radiotelemetry, using a PA-C10 transmitter, RPC-1 receiver, APR-1 30 
ambient pressure monitor, and a Data-Quest-ART-Silver 4.2 acquisition system (Data 31 
Sciences International, USA). The transmitter was placed subcutaneously. After the 32 
recovery for 1 week from the surgical procedure, systolic/diastolic BP and heart rate 33 
were measured continuously, for 10 s every 15 min, and an hourly or 3 hours mean 34 
BP was calculated in the usual manner by averaging sequential systolic/diastolic BP 35 
 3 
values. BP recording was initiated at 12 PM on day 1. BP values obtained for the first 1 
3 days at baseline were compared to those for the last 3 days with the treatment in 2 
each experiment. 3 
 4 
Blood Pressure Measurement using Tail-cuff method 5 
Systolic blood pressure (SBP) of conscious animals was measured at light phase by 6 
using tail-cuff method; BP-98A (Softron). SBP was averaged as the average of 5 7 
measurements for each mouse. SBP values of Ksp-Cre positive or negative mice 8 
were obtained by turns to minimize the effect of circadian rhythm on SBP. 9 
 10 
Protein Sample Preparation and Western Blotting 11 
Total proteins were obtained by using TNE buffer containing 10 mM Tris-HCl (pH 7.8), 12 
1% NP-40, 0.15 M NaCl, and 1 mM EDTA. Membrane fractions were obtained with 13 
MinuteTM Plasma Membrane Protein Isolation Kit (Invent Biotechnologies, Inc., USA) 14 
and resuspended in the lysis buffer containing 40 mM Tris (pH 7.4), 260 mM sucrose, 15 
1% Triton X-100, and cOmplete Protease Inhibitor (Roche, Switzerland). In order to 16 
detect phospholyrated NCC, phosphatase inhibitors (10 mM NaF, 1 mM NaP2O7, 17 
and 1 mM NaVO4) were added to all buffers. Protein concentrations were determined 18 
by BCA protein assay kit (Thermo Fisher Scientific, USA). Equal volumes of lysates 19 
were mixed with 2× Laemmli Sample Buffer, and the samples were incubated at 20°C 20 
for 30 min. Equal amounts of total proteins were loaded in each well of SDS-PAGE. 21 
The protein-transferred membranes were incubated with ECL Prime Blocking reagent 22 
for 1 h at room temperature, and further incubated with one of the primary antibodies 23 
at 4°C overnight. Following this, the membranes were incubated with 24 
peroxidase-conjugated secondary antibodies for 30 min at room temperature, and the 25 
obtained results were visualized by using ImmunoStar LD (Wako Chemicals, Japan). 26 
Bio-Safe Coomasie G-250 stain (Bio-rad) was used for CBB staining. Densitometry 27 
was done by using ImageJ 1.50i. The intensity of WB band was corrected by that of 28 
CBB staining to calculate the expression level of each protein. 29 
 30 
Antibodies 31 
  In addition to the listed antibodies in the main Methods, primary antibodies used in 32 
this study were as follows: anti-NCC (1/1000 for IHC, AB3553, Millipore); 33 
anti-HSD11B2 (1:1000 for WB; AB1296, Millipore); anti-HSD11B1 (1:1000, for WB; 34 
ab39364, Abcam); anti-AQP2 (1/100 for IHC, sc-9882, Santa Cruz Biotechnology); 35 
 4 
anti-NPM (1/3000 for WB, B0556, Sigma-Aldrich); anti-α-Tubulin (1/3000 for WB, 1 
017-25031, Wako Chemicals); anti-pan-cadherin (1/1000 for WB, C3678, Sigma). 2 
 3 
Acute Amiloride Test 4 
  At day 1 (12 PM), vehicle solution (2% dimethyl sulfoxide (DMSO) in distilled water) 5 
was intraperitoneally injected into WT and KO mice (n=4 in each group), and they 6 
were placed in a metabolic cage. Urine samples were collected at 3 PM on the same 7 
day. At day 2 (12 PM), amiloride (5 mg/KgBW) was intraperitoneally injected and the 8 
urine samples were collected at 3 PM. The samples were centrifuged at 2000 ×g for 9 
10 min at 4°C immediately after the collection, and the supernatants were used in the 10 
following analyses. Blood samples were collected from IVC after the sacrifice.  11 
 12 
Immunohistochemical Analysis 13 
Mouse kidneys were fixed with 4% paraformaldehyde (PFA) immediately following 14 
the animal sacrifice, and they were rotated overnight at 4°C. Cryosections of the fixed 15 
mouse kidneys were incubated with one of the primary antibodies overnight, which 16 
was followed by an incubation with Alexa488- or Alexa555-conjugated secondary 17 
antibodies (Jackson ImmunoResearch, USA) for 1 h at 4°C and DAPI (1/5000) at 18 
room temperature for 5 min. The images were obtained using DM14000B microscope 19 
and LAS AF software (Leica, Germany). 20 
 21 
Gene Expression Analyses 22 
  Total RNA was obtained from tissue homogenates by using RNeasy Mini Kit (Qiagen, 23 
Germany), while cDNA was synthesized using ReverTra Ace (Toyobo, Japan). Quantitative 24 
realtime PCR analysis was performed using the StepOne Plus detection system (Applied 25 
Biosystems, USA). SYBR primers used in this study are shown in Supplemental Table. 26 
 27 
  28 
 5 
Supplemental Table. SYBR primers. 1 
Gene Forword Reverse
Hsd11b2 GGCTGCTTCAAGACAGATGC TGGGCTAAGGTCAGGCAATG
Hsd11b1 GGAGCCGCACTTATCTGAAG GTAGTAGGCCAGGGAGAGCA 
Cdh16 CTTCAAGGGCATGGTCTAGG CCACCTCAGCCTTTACCAGA 
Pecam1 CTTTTCGAGGTGGTGCTGAT CCTCCAGGCTGAGGAAAACT 
NeuN CGCTGAACCCGTTGAAAAGC  TTCCCCCTGGTCCTTCTGAT  
 2 
  3 
 6 
Supplemental Reference 1 
1. Jiang L, Yang S, Yin H, Fan X, Wang S, Yao B, Pozzi A, Chen X, Harris RC, 2 
Zhang M-Z. Epithelial-specific deletion of 11β-HSD2 hinders Apcmin/+ mouse 3 
tumorigenesis. Mol Cancer Res. 2013;11(9):1040-1050.  4 
 5 
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 7 
Supplemental Figures 1 
 2 
Figure S1. Kidney-specific deletion of Hsd11b2 gene.  3 
Protein (A) and mRNA (B) HSD11B2 levels were determined in Hsd11b2KSP-/- mice 4 
(n=3) and the littermate controls (n=3). Kidney-specific gene deletion was confirmed 5 
by measuring HSD11B2 expression levels in colon. Immunofluorescence analysis (C) 6 
showed that Hsd11b2 was deleted in AQP2-expressing renal tubular principal cells. 7 
Bar represents 50 µm. Data are shown as mean ± SEM. One-way ANOVA with 8 
post-hoc Bonferroni-Holm test was used for the statistical analysis. *P<0.05, 9 
compared with the control. 10 
 11 
  12 
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 1 
Figure S2. Expression level of 11β-hydroxidehydrogenase type 1 in the kidneys of 2 
kidney-specific Hsd11b2 knockout mice.  3 
Western blot analysis of showed that the renal expression levels of HSD11B1 were 4 
not affected by kidney-specific deletion of Hsd11b2 gene. 5 
  6 
 9 
 1 
Figure S3. Transcriptional expression level of Hsd11b2 and Hsd11b1 gene in 2 
Hsd11b2-expressing tissues of kidney-specific Hsd11b2 knockout mice.  3 
RNA was obtained from kidney, aorta and brainstem of Hsd11b2Ksp-/- mice (KO, n=4) 4 
and the littermate controls (WT, n=4). The transcriptional expression level of 5 
HSD11B2 and HSD11B1 were statistically analyzed along with tissue markers 6 
between the genotypes in each tissue by using one-way ANOVA with 7 
Bonferroni-Holm test. Data are presented as mean ± SEM. N.D., not detected. 8 
*P<0.05, compared to the WT tissue; †P<0.05, compared to other tissue of each 9 
genotype.  10 
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Figure S4. 11-Dehydrocorticosterone/corticosterone ratio in urine samples, body 2 
weight, and daily food intake of the experimental animals.  3 
The ratio of 11-dehydrocorticosterone (11-DHC) and corticosterone (A, n=3 for each 4 
genotype), body weight (B, WT; n=7: KO; n=6), daily food intake (C, WT; n=7: KO; 5 
n=6) of kidney-specific Hsd11b2 knockout mice and controls. Welch’s t-test was used 6 
for the statistical analyses. *P<0.05, compared with the control. 7 
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Figure S5. Negated effect of Ksp-Cre transgene on elevating systolic BP.  2 
A, Systolic BP (SBP) values were evaluated by tail-cuff method in the WT mice 3 
(Ksp-Cre(-) Flox; n=8), the KO mice (Ksp-Cre(+) Flox; n=9). B, SBP values were also 4 
obtained from mice harboring wild-type Hsd11b2 gene without Ksp-Cre transgene 5 
(Ksp-Cre(-) WT; n=4) and those with Ksp-Cre transgene (B, Ksp-Cre(+) WT; n=5). 6 
Welch’s t-test was used for the statistical analyses between the genotypes in each 7 
experiment. Data are shown as mean ± SEM. *P<0.05, compared with the control.  8 
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Figure S6. Fractionation of membrane proteins from kidney lysates.  2 
Whole-cell kidney lysates (WCL) were separated into four fractions: PM, plasma 3 
membrane; OM, organelle membrane; Cyto, cytoplasm; Nuc, nucleus. The fraction 4 
obtained before separating PM and OM represents a total membrane fraction, and it 5 
was used as such in this study. NCC and pan-cadherin were shown to be enriched in 6 
membrane fraction, PM, and/or OM, although cytoplasmic (α-tubulin) or nuclear 7 
protein (NPM, nucleophosmin) were not. 8 
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Figure S7. Hypokalemia and NCC phosphorylation level in kidney-specific Hsd11b2 2 
knockout mice. 3 
Expression levels of renal NCC phosphorylation and plasma potassium concentration 4 
in kidney-specific Hsd11b2 knockout mice (KO) and the littermate controls (WT) are 5 
shown, including the results of chronic treatments of amiloride or high KCl diet. a.u.; 6 
arbitrary unit. 7 
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Figure S8. Continuous blood pressure (BP) measurements in kidney-specific 2 
Hsd11b2 knockout mice and wild-type controls treated with amiloride or 3 
hydrochlorothiazide, or fed by 8% KCl diet.  4 
 BP was continuously measured for 72 h in Hsd11b2Ksp-/- mice and wild-type controls 5 
(n=3 in each group) (baseline measurements). Following this, chronic amiloride in 6 
drinking water (A), 8% KCl diet (B), or chronic hydrochlorothiazide in drinking water 7 
(C) were administered to the animals (arrowhead), and BP was measured for the 8 
additional 10 days. Hourly mean blood pressures were calculated and shown as 9 
mean ± SEM. Statistical analyses were performed by using two-way ANOVA with 10 
post-hoc Bonferroni-Holm test. *P<0.05, compared with baseline BP determined in 11 
the wild-type mice. 12 
 13 
 14 
 15 
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
80
90
100
110
120
130
140
0 24 48 72 96 120 144 168 192 216 240 264 288 312
Hours
M
B
P
 (m
m
H
g)
● WT
KO
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●●
●
●●●●
●
●●
●
●
●
●●
●
●
●
●
●●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
80
90
100
110
120
130
140
150
0 24 48 72 96 120 144 168 192 216 240 264 288 312
Hours
M
B
P
 (m
m
H
g)
● WT
KO
●
●●
●
●
●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●●
●
●●
●
●●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
80
90
100
110
120
130
140
150
0 24 48 72 96 120 144 168 192 216 240 264 288 312
Hours
M
B
P
 (m
m
H
g)
● WT
KO
Amiloride
8% KCl
HCTZ
Baseline
Baseline
Baseline
*
*
*
A
B
C
N.S.
N.S.
N.S.
